Phase 2 N=33 Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Adult Idiopathic Generalized Osteoporosis
Primary: Percent Change in Lumbar Spine Areal BMD by DXA — 5.2 percentage of change
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=26 Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T
HIV
Primary: Treatment-emergent Adverse Events — 3; 6; 11; 3 participants
Phase 2 N=535 Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
Myocardial Infarction · Acute Coronary Syndromes · Unstable Angina
Primary: The Composite Endpoint of Death, Periprocedural Myonecrosis (PPM), Urgent Target Vessel Revascularization (uTVR) or Major Bleeding — 69; 60; 48 Participants
Phase 2 N=70 Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial
Chronic Kidney Disease
Primary: Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks — 1.1; 0.3 Percentage change
Phase 2 N=15 Role of Mirtazapine in Ameliorating Sleep Disordered Breathing
Spinal Cord Injuries · Sleep Disordered Breathing
Primary: CO2 Reserve (Delta-PETCO2-AT) — -3.8; -2.0 mmHg — p=0.015
Phase 2 N=292 A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Change in HbA1c After 12 Weeks of Treatment — 0.24; -0.31; -0.44; -0.56 percentage of glycated hemoglobin — p=< 0.0001
Phase 2 N=120 Colchicine Plus Phenolic Monoterpenes to Treat COVID-19
COVID-19
Primary: Mortality Rate — 6; 1 Participants — p=0.0318
Phase 2 N=56 Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Neuralgia · Myalgia
Primary: Neuromuscular Symptoms — 36.5; 43.5; 28.5; 32.7 score on a scale — p=<0.01
Phase 2 N=20 A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)
15q Duplication Syndrome · CDKL5 Deficiency Disease
Primary: Percent Change From Baseline in Motor Seizure Frequency Per 28 Days During the Maintenance Period — 11.7; -23.6 percent change
Phase 2 N=28 Metabolic Effects of Betaine Supplementation
Obesity · Dysglycemia
Primary: Fasting and 2 Hour Glucose Levels, Comparing Baseline and 12 Weeks. — -5; 3; 7; -4 mg/dl
Phase 2 N=62 Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis
Sickle Cell Disease · Vaso-Occlusive Crisis
Primary: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 4; 4; 26 Participants
Phase 2 N=170 Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Melanoma (Skin)
Primary: Safety of the Peptide Vaccines — 4; 7; 2; 1 Participants
Phase 2 N=76 PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Small Cell Lung Cancer · Gastric Adenocarcinoma · Esophageal Adenocarcinoma
Primary: Clinical Benefit Rate (CBR) at 24 Weeks of PDR001+LAG525 by Tumor Type in Multiple Solid Tumors and Lymphoma — 25; 3; 2; 5 Participants
Phase 2 N=258 Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
Chronic Hand Eczema
Primary: Investigator's Global Assessment for Chronic Hand Eczema (IGA-CHE) Score of 0 (Clear) or 1 (Almost Clear) With at Least a 2-step Improvement (IGA-CHE Treatment Success)…
Phase 2 N=143 Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP) at Week 12 — -0.75; -1.10; -2.10; -2.43 score on a scale — p=0.38